Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IMO....partner with a foreign or an multi-national pharma.
So 7.6 million sold to ppl who BOUGHT at above .10!! Nice!
You beat me to it...was just about to post it. :)
You seem to have done your DD. Advice taken proportionate to your number of post on this board. :)
Cool! Confirmation that lots of Pharma knows about Lympro (seems like they know more than the company..amazing!) Buy now or buy later...doesn't matter, but seems a lot of ppl just want to buy! Lol
So what you are saying is he has an agenda? ;)
I welcome this breather today. Reset for the next leg up.
"I could establish a few collaborations with biotech companies in SF and physicians at UCSF. We are moving to the next step on our quest for a cure for Wolfram Syndrome. I feel that a cure for Wolfram could lead to a cure for diabetes and blindness. Thank you for your support. "
http://wolframsyndrome.blogspot.com/2014/06/update-from-san-francisco-5-cure-for.html?spref=tw
$AMBS 6/17: .116 5/16: .0825 4/17: .0697. Fire!
Extremely bullish with big catalysts/milestones in July
$AMBS 6/17-.116 5/16-.0825 4/17-.0697
Extremely bullish with big catalysts/milestones in July
If a few of the milestones/catalysts are met...a RS will indeed not be necessary. Will be an exciting 2h 2014!
Current Milestones and Catalysts
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
Green everyday this week. Go $AMBS. Loaded with experienced execs and licensed doctors! Check out sticky for catalysts.
Current Milestones and Catalysts
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
(Above credit goes to Brick for posting)
Soooo....what's the email date again?
Here's a hint: Www.ama**n*us.com. You fill in the blank.
Great bullish close above .10 today.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103178057
You are correct Warp....my DD also has revealed that all of the scientists and doctors working for AMBS are fully licensed. Very respected individuals in their respective fields of expertise.
My DD has revealed that all researchers and medical personnel working for or advising the company are fully licensed and experts in their respective fields.
Brick gets credit for the post. I copied to a new post so I can put it in sticky.
Current Milestones and Catalysts
LymPro
• Pilot clinical performance data (1H-14);
• Retrospective / prognostic 9 year patient record clinical study (1H-14);
• Clinical Performance studies to support CLIA registration (1H-14);
• Commercial Launch as a Laboratory-Developed Test (“LDT”) under CLIA (2H- 2014);
Eltoprazine
• Evaluate best indication for commercial development (1H/14)
• Initiate Phase 2b Clinical Trial (1H/14)
MANF
• Retinitis Pigmentosa: functional genetic mouse model (1H-14)
• Parkinson’s disease: CED delivery data w/Renishaw (1H-14)
• Preliminary systemic toxicology (PK/PD relationship) (1H-14)
• Wolfram Syndrome enablement (Diabetes)
(Above credit goes to Brick for posting)
Agreed. Truly pathetic.
Wow...superb post Warp!
Totally agree, we've had this discussion a while back. MJFF is not the end all in Parkinson's research/grant/etc.
More like 6-8 chances in the last couple years. Lol
Combating Wolfram Syndrome
Wednesday, June 4, 2014
MANF, Wolfram, and Diabetes #3: Protecting remaining tissues
I am getting many questions about MANF, and many people are looking at my blogs related to this topic.
http://wolframsyndrome.blogspot.com/2014/01/manf-wolfram-and-diabetes-what-is-manf.html
http://wolframsyndrome.blogspot.com/2014/04/manf-wolfram-and-diabetes-part2.html
We became interested in MANF several years ago. Although we have not published any articles related to MANF, we have been accumulating data. The reason we are actively studying MANF is that this molecule may be able to protect remaining pancreatic beta cells and brain cells in patients with Wolfram syndrome and type 1 diabetes. I will tell you more about our strategy in my next blog.
http://wolframsyndrome.blogspot.com/2014/05/four-pillars-to-provide-cure-for.html
Fumihiko Urano at 6:41 AM
You should see the words "MANF -> biomarkers" on the left side of the whiteboard.
Agreed. Just listened to the replay of Gerald's presentation. Great presentation (one of his best IMO) and everything appears to be on track. Also sounds like they will open the floodgates in July at the Copenhagen conference. Daily up/down penny ticks will be meaningless soon.
Some got impatient and sold.
Everyone expects blockbuster announcements (the high expectations that are set here doesn't help either)....the result is let downs when big news isn't released at the conference.
Soon they will have everyone in the scientific community working for them! Go AMBS!
Was going to post the BMS deal too Zoom. You beat me to it! Go $AMBS!!
Progress looking great compared to last year. Severely undervalued here. Great job everyone on the updates.
Thanks brick. Voted.
Thanks for the DD Warp! I understand that it is more important to file late than file inaccurately. One concern is they had the entire 1st quarter to prepare the 10-K, it's not like they didn't know that it was coming. In order to become a world class company, these controllable events should be prevented in order to instill shareholders and potential partner confidence.
Realistically, in the real world, ppl lose their jobs for these types of oversight.
PS...still a diehard AMBS supporter.
MARCUM LLP is the auditor
With so many people with the experience they have at AMBS...there is absolutely no excuse should a late filing occur. I know many here (INCLUDING MUSELF) who has emailed the company asking about the 10-k. Plus they filed the extension so they know exactly when it is due. With all that said, I say the 10-K has been filed or they have been bought out! Lol wishful thinking.
Not how "I" define AMBS. Haven't checked most current but we should still be +20% YTD PPS. y
You should buzz around at another stock.
MMs are definitely playing into the fear to get cheap shares.
Looking forward to big announcements soon.
GO $AMBS!!
Lol....let's hope so. Aloha!
Jan 2014 to April 2014 = +23% Loving the underperformance!